SCHEMBL496443

SCHEMBL496443

C[C@H]1Oc2ccc(NC(=O)c3ccc(Cl)cc3N[C@@H]3CCCC[C@@H]3N3CCCC3)cc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.40
SMYD3 Q9H7B4 3/20 0.39
KDM4E B2RXH2 1/20 0.38
KDR P35968 1/20 0.38
PARP1 P09874 5/20 0.37
TSHR P16473 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
TRPV1 Q8NER1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL495907 0.79 HSD11B1 (0.39) HSD11B1KDM4ETSHRNPC1RAB9A
Hydrochloric Acid SCHEMBL495905 0.79 HSD11B1 (0.40) HSD11B1NPC1RAB9AMEN1KMT2A
Hydrochloric Acid SCHEMBL495906 0.79 HSD11B1 (0.40) HSD11B1NPC1RAB9AMEN1KMT2A
SCHEMBL496067 0.76 TRPV1 (0.51) HSD11B1TRPV1
SCHEMBL2709701 0.75 TRPV1 (0.50) TRPV1
Hydrochloric Acid SCHEMBL496283 0.75 TRPV1 (0.50) TRPV1
Hydrochloric Acid SCHEMBL496470 0.75 TRPV1 (0.49) TRPV1
SCHEMBL496278 0.75 SCN8A (0.39) SMYD3PARP1TSHRTRPV1
SCHEMBL496349 0.73 SCN8A (0.44) SMYD3TRPV1
SCHEMBL495996 0.72 SIGMAR1 (0.48) KDM4ETSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP claimed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US claimed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US claimed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP claimed
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 HSD11B1 4081/4885SMYD3 3591/4885KDM4E 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.